Notable financing and leadership movements include SpliceBio’s $135 million Series B to advance Stargardt disease gene therapy and Oncolytics Biotech’s appointment of Jared Kelly as CEO to expedite immunotherapy development. Nicoya Lifesciences acquired Applied Photophysics to enhance biologics characterization with biophysical instrumentation, aligning technologies for drug development. These developments reflect ongoing sector investment and organizational evolution amidst a challenging funding environment.